tradingkey.logo

Aptose Biosciences Q3 net loss narrows

ReutersNov 13, 2025 10:12 PM


Overview

  • Aptose reports Q3 net loss of $5.1 mln, down from $7.0 mln last year

  • Research and development expenses decreased due to reduced clinical and manufacturing activity


Outlook

  • Company did not provide specific financial guidance


Result Drivers

  • R&D: Research and development expenses decreased by $2.5 million to $2.2 million for the quarter ended September 30


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Income

-$5.12 mln

Press Release: ID:nGNX3Tlhr0

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI